Speaker Profile
Ph.D., CEO, Quibim
Biography
Angel Alberich-Bayarris has 15 years of experience in the field of medical imaging and computer vision, he possesses deep knowledge of the challenges and opportunities in diagnostics and drug development. He has worked in the development of several algorithms for Imaging Biomarkers analysis that promoted the creation of the company QUIBIM (Quantitative Imaging Biomarkers in Medicine), focused in the creation of a platform for the analysis of Imaging Biomarkers. He is a member of the board of the European Society of Medical Imaging Informatics (EUSOMII) and of the e-Health and Informatics Subcommittee of the European Society of Radiology (ESR). Alberich-Bayarri is the author of more than 100 articles in prestigious international journals, author of 20 book chapters and editor of 2 books. He received the MIT Innovators Under 35 award in 2015.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA
